RU2015130730A - METHOD FOR PREDICTING SENSITIVITY TO CHEMOTHERAPY IN PATIENTS WITH LYMPHO-PROLIFERATIVE DISEASES - Google Patents
METHOD FOR PREDICTING SENSITIVITY TO CHEMOTHERAPY IN PATIENTS WITH LYMPHO-PROLIFERATIVE DISEASES Download PDFInfo
- Publication number
- RU2015130730A RU2015130730A RU2015130730A RU2015130730A RU2015130730A RU 2015130730 A RU2015130730 A RU 2015130730A RU 2015130730 A RU2015130730 A RU 2015130730A RU 2015130730 A RU2015130730 A RU 2015130730A RU 2015130730 A RU2015130730 A RU 2015130730A
- Authority
- RU
- Russia
- Prior art keywords
- chemotherapy
- activity
- courses
- result
- complete
- Prior art date
Links
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Способ прогнозирования чувствительности к химиотерапии у больных с лимфопролиферативными заболеваниями, включающий определение в сыворотке крови количественных уровней маркеров путем анализа сыворотки крови до и после первого курса химиотерапии, отличающийся тем, что в сыворотке крови до начала химиотерапии определяют активность ТК-1 и концентрацию β2-МГ, а также после первого курса химиотерапии активность ТК-1, и если:- активность ТК-1 до начала лечения <150,0 ДЕд/л, то в результате 6-8 курсов химиотерапии достигается полная или частичная ремиссия;- уровень β2-МГ до начала лечения <2200,0 мкг/л, то в результате 6-8 курсов химиотерапии достигается полная или частичная ремиссия;- активность ТК-1 до начала лечения <150,0 ДЕд/л и/или уровень β2-МГ до начала лечения <2200,0 мкг/л, то в результате 6-8 курсов химиотерапии достигается полная или частичная ремиссия;- активность ТК-1 после 1 курса химиотерапии возрастает более чем в 4 раза относительно исходного значения, то в результате 6-8 курсов химиотерапии достигается полная или частичная ремиссия.A method for predicting sensitivity to chemotherapy in patients with lymphoproliferative diseases, including determining serum quantitative levels of markers by analyzing blood serum before and after the first course of chemotherapy, characterized in that TK-1 activity and β2-MG concentration are determined in blood serum before chemotherapy , as well as after the first chemotherapy course, the activity of TK-1, and if: - the activity of TK-1 before treatment is <150.0 DU / L, then as a result of 6-8 courses of chemotherapy, full or partial re mission; - β2-MG level before treatment <2200.0 μg / l, then complete or partial remission is achieved as a result of 6-8 courses of chemotherapy; - TK-1 activity before treatment <150.0 DU / L and / or the level of β2-MG before treatment is <2200.0 μg / l, then complete or partial remission is achieved as a result of 6-8 courses of chemotherapy; - the activity of TK-1 after 1 course of chemotherapy increases more than 4 times relative to the initial value, then As a result of 6-8 courses of chemotherapy, complete or partial remission is achieved.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2015130730/15A RU2593020C2 (en) | 2015-07-24 | 2015-07-24 | Method for prediction of sensitivity to chemotherapy in patients suffering from lymphoproliferative diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2015130730/15A RU2593020C2 (en) | 2015-07-24 | 2015-07-24 | Method for prediction of sensitivity to chemotherapy in patients suffering from lymphoproliferative diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2015130730A true RU2015130730A (en) | 2016-01-10 |
RU2593020C2 RU2593020C2 (en) | 2016-07-27 |
Family
ID=55071882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2015130730/15A RU2593020C2 (en) | 2015-07-24 | 2015-07-24 | Method for prediction of sensitivity to chemotherapy in patients suffering from lymphoproliferative diseases |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2593020C2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2702657C1 (en) * | 2019-06-03 | 2019-10-09 | федеральное государственное бюджетное образовательное учреждение высшего образования "Новосибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО НГМУ Минздрава России) | Method for prediction of clinical effectiveness in the patients with acute myeloblastic leukemias with anti-tumor preparations daunorubicin and cytosine-arabinoside |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2533816C2 (en) * | 2013-03-11 | 2014-11-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Новосибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО НГМУ Минздрава России) | Method of predicting efficiency of treatment of patients with high grade non-hodgkin lymphoma |
RU2542505C1 (en) * | 2013-07-30 | 2015-02-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия "Министерства здравоохранения Российской Федерации (ГБОУ ВПО НижГМА Минздрава России) | Method for prediction of chemotherapeutic effectiveness in patients with malignant new growths of epithelial tissues |
-
2015
- 2015-07-24 RU RU2015130730/15A patent/RU2593020C2/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
RU2593020C2 (en) | 2016-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201991105A1 (en) | RISK ASSESSMENT METHODS USING TOTAL AND SPECIFIC NON-CELLULAR DNA | |
MX2018012580A (en) | Methods and kits for the diagnosis and risk stratification of patients with ischemia. | |
MX2020001193A (en) | Methods for determining dpp3 and therapeutic methods. | |
EA201790769A1 (en) | DETERMINATION OF THE LEVELS OF GLYCOSAMINOGLICANES BY THE MASS SPECTROMETRY METHOD | |
WO2018183817A3 (en) | Tumor burden as measured by cell free dna | |
RU2016147122A (en) | APPLICATION OF SERELAXIN TO REDUCE GDF-15 | |
RU2015130730A (en) | METHOD FOR PREDICTING SENSITIVITY TO CHEMOTHERAPY IN PATIENTS WITH LYMPHO-PROLIFERATIVE DISEASES | |
RU2014113841A (en) | METHOD FOR EARLY DIAGNOSTICS OF ENDOGENOUS INTOXICATION | |
EA201891693A1 (en) | METHOD FOR PREDICTING THE RESULTS OF TREATING AFLIBERCEPT A PATIENT PREFERREDLY SUFFERING FROM CANCER BY MEASURING BIOMARKER LEVEL IN THE BLOOD PLASMA | |
EA201401101A1 (en) | METHOD OF LABORATORY DIAGNOSTICS OF PNEUMONIA | |
EA202190962A2 (en) | EXPRESSION LEVELS OF IMMUNOGLOBULINS AS A BIOLOGICAL MARKER FOR THE RESPONSE TO THE PROTEASOME INHIBITOR | |
MX2019002269A (en) | Monoclonal antibody against melk and utilization thereof. | |
RU2017132274A (en) | METHODS FOR DIAGNOSIS OF CHRONIC VALVE DISEASE | |
RU2016101941A (en) | A method for the diagnosis of threatening preterm birth | |
EA201600668A2 (en) | METHOD OF MONITORING THE EFFICIENCY OF ANTI-TUMOR TREATMENT OF NON-SMALL CELL LUNG CANCER | |
EA201691393A1 (en) | METHODS OF SUBSTRATE CLEARANCE ANALYSIS FOR LIZOSOMAL ENZYMES | |
RU2015117686A (en) | Determination of the content of the GC-rich genome sequence (GC-DNA) in the circulating extracellular DNA of peripheral blood plasma as a way to determine the level of cell death in chronic diseases, physiological conditions (pregnancy) and the chronic effects of adverse environmental factors on the human body | |
BR112017007592A2 (en) | polypeptide, polypeptide composition, polypeptide production and antibody detection methods, use of polypeptide and reagent kit | |
RU2017127218A (en) | LABORATORY METHOD FOR IDENTIFYING THE COMMON STAGES OF LYMPHO-PROLIFERATIVE DISEASES | |
RU2014128849A (en) | METHOD FOR DIAGNOSTIC OF GASTROESOPHAGELIC REFLUX DISEASE IN CHILDREN | |
Miller et al. | Vitamin D Binding Protein And Alpha-1-Acid Glycoprotein Levels In Serum Are Associated With Lymphangioleiomyomatosis | |
RU2013132754A (en) | METHOD FOR FORECASTING DEVELOPMENT OF ACQUIRED MYOPERITY IN SCHOOLCHILDREN | |
UA106446U (en) | A method for diagnosing endothelial dysfunction and its correction in patients with acute epididymitis | |
UA114894U (en) | METHOD OF DIAGNOSIS AND DETERMINATION OF THE Severity and Type of Multiple Sclerosis at an Early Stage of Disease | |
RU2014131431A (en) | METHOD FOR DIAGNOSTIC OF TREASURY NERVE NEURALGIA FOR CARRYING OUT DIFFERENTIATED THERAPY |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20200725 |